- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02586194
Pharmacokinetics Study in Patients With Impaired Hepatic Function
Pharmacokinetic Study of ASP015K - Evaluation of Pharmacokinetics in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Fukuoka, Japan
- Site JP00001
-
Kanagawa, Japan
- Site JP00003
-
Tokyo, Japan
- Site JP00006
-
Tokyo, Japan
- Site JP00004
-
Tokyo, Japan
- Site JP00005
-
Tokyo, Japan
- Site JP00002
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
A subject is eligible for the study if all of the following apply:
All subjects:
- Body weight: ≥40.0 kg and <90.0 kg
- Body mass index (BMI): ≥17.0 and <30.0 kg/m2
Female subject must either:
- Be post-menopausal or surgically sterile.
- Agree not to try to become pregnant starting at the time of informed consent throughout the study period and for 60 days after the final study drug administration if she is of childbearing potential.
- Agrees to use highly effective contraception
- Agrees not to donate sperm (for male)/ ova (for female) starting at the time of informed consent, and throughout the study period and for 90/60 days after the final study drug administration.
- Female subject agrees not to breastfeed starting at the time of informed consent, and throughout the study period and for 60 days after the final study drug administration.
- Agrees not to participate in a clinical trial, a post-marketing study, or a clinical study during the period from informed consent to post examination.
A patient with impaired hepatic function:
- Impaired hepatic function Child-Pugh Score Class A (mild, 5-6 points) or Class B (moderate, 7-9 points).
A subject with normal hepatic function:
- Healthy, as judged by the investigator/subinvestigator based on physical examinations and all tests obtained at screening and during the period from hospital admission to immediately before study drug administration.
Exclusion Criteria:
A subject will be excluded from participation in this study if any of the following apply:
All subjects:
- Received or is scheduled to receive any investigational drugs in other clinical trials, post-marketing studies or clinical research within 120 days before screening or during the period from screening to the hospital admission.
- Excessive alcohol or smoking habit.
Applies to any of following concerns of tuberculosis:
- A history of active tuberculosis
- Abnormalities detected on a chest X-ray test (at screening)
- Contact with infectious tuberculous patients
Applies to any of following concerns except for tuberculosis:
- Concurrent or previous severe herpes zoster or herpes zoster disseminated
- More than 1 recurrence of localized herpes zoster
- Inpatient hospital care for severe infectious disease within 90 days before the hospital admission
- Treatment with intravenous antibiotics within 90 days before the hospital admission (prophylactic antibiotics are not applicable)
- Other than above, a people who has a risk of developing infectious diseases (e.g. urethral catheterisation) in judgment of the investigator/subinvestigator
- Vaccination of live vaccines or live attenuated vaccines within 56 days before the hospital admission (inactivated vaccines such as influenza vaccine and pneumococcal vaccine are not applicable).
- Concurrent or previous drug allergies.
- A history of clinically serious allergies (serious allergies: Generalised urticaria which requires hospital admission, allergy which causes anaphylactic shock, etc.).
- Concurrent or previous cardiac failure NYHA class 3 or 4, long QT syndrome and congenital short QT syndrome.
- Development of (an) upper gastrointestinal symptom(s) within 7 days before the hospital admission.
- Concurrent or previous lymphatic disease.
- A history of digestive tract excision, except for a history of appendectomy.
- Previous use of ASP015K.
A patient with impaired hepatic function:
- Unable to start washout of concomitant prohibited medications from at least 14 days prior to the study drug administration.
- Concurrent uncontrolled hypertension.
- Clinically significant abnormality detected on standard 12-lead electrocardiogram at screening or hospital admission.
- eGFR by the GFR estimating equation for Japanese <45 mL/min/1.73 m2 (the first decimal place rounded off) at screening.
- Uncontrolled ascites or pleural effusion observed at screening.
- Concurrent hepatic encephalopathy Coma Scale II or more at screening.
- Underwent hepatic transplantation, or underwent hepatectomy within 1 year before screening.
- Concurrent or previous drug-induced hepatic disorder.
- Concurrent acute hepatic disease.
- With surgically-placed portosystemic shunts including transjugular intrahepatic portosystemic shunts.
- Concurrent biliary obstruction.
- A history of oesophageal haemorrhage or gastric varices haemorrhage within 180 days before screening.
- Irregular or acute, and clinically significant LFT values or changes in clinical symptoms from 30 days before screening to immediately before study drug administration.
- Platelet count <4 × 104/μL, or haemoglobin <9 g/dL at screening.
- Alcohol dependence or unable to remain abstinent during the specified period.
- Concurrent esophagus or gastric varices which have a high risk of clinically significant haemorrhage.
- Concurrent cerebrovascular disorder, serious heart disease, malignant tumour or a history within 5 years before screening, gastrointestinal disease, urinary disease, renal disease, endocrine disease, and respiratory disease.
A subject with normal hepatic function:
- Received or is scheduled to receive medications (including over-the-counter drugs) within 7 days before the hospital admission.
- Deviates from any of the normal range of blood pressure, pulse rate, body temperature and standard 12-lead electrocardiogram at screening or the hospital admission.
- Meets any of the criteria for laboratory tests at screening or the hospital admission.
- eGFR by the GFR estimating equation for Japanese <60 mL/min/1.73 m2 (the first decimal place rounded off) at screening.
- Concurrent or previous hepatic disease, cerebrovascular disorder, malignant tumor, heart disease, gastrointestinal disease, except for a history of appendicitis, renal disease, endocrine disease, respiratory disease, urological disease.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Control (Subjects with normal hepatic function)
Oral
|
Oral
|
Eksperimentell: Mild hepatic impairment
Oral
|
Oral
|
Eksperimentell: Moderate hepatic impairment
Oral
|
Oral
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Sikkerhet vurdert av vitale tegn
Tidsramme: Inntil 7 dager etter dosering av studiemedikamentet
|
Ryggliggende blodtrykk, liggende puls og aksillær kroppstemperatur
|
Inntil 7 dager etter dosering av studiemedikamentet
|
Sikkerhet vurdert ved laboratorietester
Tidsramme: Inntil 7 dager etter dosering av studiemedikamentet
|
Hematologi, blodbiokjemi og urinanalyse
|
Inntil 7 dager etter dosering av studiemedikamentet
|
Pharmacokinetics (PK) parameter of ASP015K: AUCinf
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72 hr after dosing
|
AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameter of ASP015K: Cmax
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Cmax: Maximum concentration
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameter of metabolites: AUCinf
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
|
PK parameter of metabolites: Cmax
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
|
Safety assessed by AEs
Tidsramme: Up to 7 days after the study drug dosing
|
Up to 7 days after the study drug dosing
|
|
Safety assessed by 12-lead ECGs
Tidsramme: Up to 7 days after the study drug dosing
|
Up to 7 days after the study drug dosing
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
PK parameters of ASP015K: AUClast
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameters of ASP015K: t1/2
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
t1/2: Terminal elimination half-life
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameters of ASP015K: tmax
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
tmax: Time of Cmax
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameters of ASP015K: CL/F
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
CL/F: Apparent total systemic clearance
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameters of ASP015K: Vz/F
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Vz/F: Apparent volume of distribution during the terminal elimination phase
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
PK parameters of metabolites: AUClast
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
|
PK parameters of metabolites: t1/2
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
|
PK parameters of metabolites: tmax
Tidsramme: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 015K-CL-PK10
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på ASP015K
-
Astellas Pharma Global Development, Inc.FullførtFriske Frivillige | Farmakokinetikk til ASP015K | MateffektForente stater
-
Astellas Pharma IncFullførtPasienter med nedsatt nyrefunksjonJapan
-
Astellas Pharma IncFullførtSunne fag | Biotilgjengelighet av ASP015K | Farmakokinetikk til ASP015KForente stater
-
Astellas Pharma IncFullførtSunne fag | Farmakokinetikk til ASP015KForente stater
-
Astellas Pharma China, Inc.Fullført
-
Astellas Pharma IncFullførtSunne fag | Farmakokinetikk til ASP015KForente stater
-
Astellas Pharma IncFullførtSunne fag | Farmakodynamikk | Farmakokinetikk til ASP015KForente stater
-
Astellas Pharma IncFullførtLeddgikt, revmatoidJapan, Korea, Republikken, Taiwan
-
Astellas Pharma Global Development, Inc.FullførtLeddgikt, revmatoidForente stater, Polen, Tsjekkia, Bulgaria, Ungarn, Mexico
-
Astellas Pharma IncFullførtSunne fag | Biotilgjengelighet av ASP015K | Farmakokinetikk til ASP015KForente stater